Vesugen
Research OnlyA synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support vascular health by modulating endothelial gene expression. The only published primary research is Russian in-vitro work on cultured endothelium. No animal vascular studies, no human clinical validation, and no regulatory approval anywhere.
KED-vascular · Lys-Glu-Asp (vascular) · Vascular tripeptide
Preclinical evidence only
- Preclinical
- 100%
- Human research
- 0%
Based on 2 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
The proposed mechanisms of Vesugen are based entirely on Russian research from the St. Petersburg Institute of Bioregulation and Gerontology. No independent Western validation exists.
How It Works (Simplified)
Vesugen targets vascular health through endothelial gene modulation and related pathways:
Binds to DNA sequences in endothelial cells, modulating expression of genes related to vascular tone, permeability, and cell function.
May influence nitric oxide signaling and endothelial-dependent vasodilation, supporting healthy blood flow and vascular reactivity.
Proposed to reduce oxidative stress in vascular tissue, protecting endothelial cells from age-related damage and dysfunction.
Claimed to counteract age-related changes in vascular gene expression patterns, potentially supporting healthier vascular aging.
Key Context: All research originates from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson’s institute). No independent Western validation exists for any claimed mechanisms.
Important Limitations
- 100% of research from Russian institutes associated with Khavinson
- No independent Western replication of any findings
- Only in-vitro (cultured-cell) studies exist; no animal vascular studies
- No human studies of any kind have been published
- Human pharmacokinetics, bioavailability, and optimal dosing unknown
- Translation from cell culture to meaningful cardiovascular benefits is unconfirmed
- Regulatory status: Not approved anywhere; unregulated research peptide
Based on in-vitro data only: changes in endothelial gene expression (e.g. endothelin-1, connexin) have been observed in cultured cells. No human time-course data exist.
PMID:28539025No animal or human dosing-response data exist for KED in vascular tissue. Russian protocols are described anecdotally as 10-20 day cycles, but these are not supported by published pharmacological studies.
In-vitro studies report effects on vascular-cell renewal markers (Ki-67, p53) and adhesion molecules (E-selectin). No measured effects in animals or humans are documented.
PMID:25408528No long-term human data exist. Optimal treatment duration and cycling protocols are not established, and human pharmacokinetics are unknown.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Cardiogen
CompatibleBoth Khavinson cardiovascular peptides - Cardiogen targets heart muscle, Vesugen targets blood vessel endothelium. May have complementary vascular system effects.
Epithalon
CompatibleBoth Russian bioregulator peptides with different targets - epithalon for telomerase/longevity, Vesugen for vascular health. No known direct interactions.
Thymalin
CompatibleBoth developed within Russian peptide bioregulation research - Thymalin for thymus/immunity, Vesugen for vascular endothelium. No known contraindications.
BPC-157
CompatibleDifferent vascular mechanisms - BPC-157 promotes angiogenesis and tissue healing, Vesugen targets endothelial gene expression. Potentially complementary for vascular health.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Vesugen
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-14 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01 · Evaxion EVX-01
EVX-01 is an investigational, patient-specific neoantigen peptide vaccine studied with anti-PD-1 therapy in advanced melanoma. Two small single-arm cohorts show vaccine-specific T-cell responses and observed tumor responses, but they cannot establish how much EVX-01 adds to checkpoint treatment.
Compared With
4 comparisonsConditions Studied
3 entries- Vesugen for Cardiovascular Health Vesugen is marketed for cardiovascular support based on claimed effects on vascular endothelium gene expression. Russian in-vitro…
- Vesugen for Vascular Aging Vesugen is proposed to counteract age-related vascular changes by modulating endothelial gene expression. In-vitro studies in agin…
- Vesugen for Endothelial Function The proposed primary target of Vesugen is vascular endothelium. Cell culture studies show gene expression changes in endothelial c…